Analytical Data
-
Gene name
PROCA1
- Application
-
Alternative Names
PROCA1; Protein PROCA1; Protein interacting with cyclin A1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8NCQ7
-
Expression Region
1-364 aa
-
AA Sequence
MWVRTTLTIE RWTKEKTEPK ARSWDESLSD VNRLPSWERG HLLAGVASST DVSTFSEGGD CKEPDKCCWR HKQCTGHIIY PFASDCVRHS LHLHSVNHCN CNSRLKDSSE DSSSSRGAGP TCSHVIESPC FELTPEEEHV ERFRYGWCKS YRPVSVAVIH HPLYHECGAD DLNEEEEEEE EESKPPIPTQ VGPATASPDL GTSMATGTPD STAPITIWRS ESPTGKGQGS KVIKKVKKKK EKEKDKEEMD EKAKLKKKAK KGQLTKKKSP VKLEPSPPDV SRSLSARQLA RMSESSPESR EELESEDSYN GRGQGELSSE DIVESSSPRK RENTVQAKKT GAKPSQARKV NKRKSPPGSN PNLS
-
Molecular Weight
40.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PROCA1, a recombinant protein derived from the PROC gene, has garnered significant attention in biomedical research due to its essential role in the regulation of anticoagulation processes in the human body. The PROC gene encodes protein C, a vitamin K-dependent plasma protein that, upon activation, plays a crucial role in the coagulation cascade by inactivating factors Va and VIIIa, thereby preventing excessive blood clotting. Mutations in the PROC gene can lead to protein C deficiency, increasing the risk of thrombotic disorders, such as venous thromboembolism. Researchers have been focusing on the development of PROCA1 as a therapeutic agent, given its potential applications in treating coagulation disorders and its use as a biomarker for assessing thrombotic risk. Advances in recombinant DNA technology have facilitated the production of PROCA1 in various expression systems, enabling detailed studies on its structure, function, and interactions with other proteins in the coagulation pathway. Understanding the role of PROCA1 could lead to novel therapeutic strategies and improved management of coagulation-related diseases.
